STOCK TITAN

CannaPharmaRx Acquiring Oklahoma Cannabis Facility

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Rhea-AI Summary

CannaPharmaRx, Inc. (OTC PINK:CPMD) announced a Letter of Intent to acquire a cannabis facility in Braman, Oklahoma, comprising 35,000 square feet of cultivation capacity, with an expansion planned to 65,000 square feet by year-end 2022. This facility is expected to generate annual revenue of approximately $21 million, contributing to total projected revenues of $40-$50 million for the company. The acquisition, involving a secured note and transfer of licenses, is set to finalize before March 31, 2022, with first harvest anticipated shortly after closing.

Positive
  • Acquisition of cannabis facility expected to generate $21 million in annual revenue.
  • Projected combined revenues from both facilities estimated at $40-$50 million.
  • Company has received oral commitments for offtake agreements prior to harvesting.
Negative
  • None.

CALGARY, AB / ACCESSWIRE / February 10, 2022 / CannaPharmaRx, Inc. (OTC PINK:CPMD), a future leader in ultramodern, highly efficient cannabis production facilities announced today that it has signed a Letter of Intent (LOI) to purchase an operating Cannabis facility located in Braman, Oklahoma.

The property consists of 35,000 square feet of cultivation capacity, with a planned, phased expansion to 65,000 square feet, by the end of 2022 and up to five harvests per year. The purchase will be completed via a secured note and will include the transfer of licenses. The transaction is expected to close prior to March 31, 2022.

The facility has ongoing growing and sales operations and should the deal be finalized CannapharmaRx will realize first harvest and sales from this property on closing. The estimated annual revenue is approximately $21 million. Between the current Cremona facility and this facility, the Company anticipates combined annual revenues of $40 - $50 million.

The Company, in addition to existing sales in Oklahoma, has received oral commitments for offtake agreements for both facilities and should finalize these deals prior to harvesting.

"The company continues to achieve significant milestones and should start to recognize significant revenue during early Q2. We continue to identify other areas for potential expansion and are confident in distribution on several continents by the middle of this year," commented Nick Colvin, CEO of CannapharmaRx.

About CannapharmaRx, Inc.

CannapharmaRx is focused on the acquisition and development of state-of-the-art cannabis grow facilities in Canada. CPMD is in discussion with other companies regarding potential acquisitions. CannapharmaRx's business strategy is to become a leader in high quality and low-cost production of cannabis through the development, acquisition, and enhancement of existing facilities. CannapharmaRx is committed to operating high-quality facilities utilizing the latest technology in combined heat and power generation to ensure being a low-cost producer of cannabis.

Safe Harbor Statement

Cautionary Note Regarding Forward-Looking Information or Statements

This press release contains forward-looking information or statements. All statements that are or information which is not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations, or beliefs of future performance, are 'forward-looking information or statements.' Forward-looking information or statements can be identified by the use of words such as 'plans,' 'expects,' or 'does not expect,' 'is expected,' 'estimates,' 'intends,' 'anticipates,' or 'does not anticipate,' or 'believes,' or variations of such words and phrases or statements that certain actions, events or results 'may,' 'could,' 'would,' 'might' or 'will' be taken, occur or be achieved. With respect to forward-looking information and statements contained herein, Management of CannapharmaRx has made numerous assumptions, including, among other things, assumptions about general business and economic conditions. Such forward-looking statements are based on assumptions and involve known and unknown risks, uncertainties, and other factors that may cause actual results, events, or developments to be materially different from any future results, events, or developments expressed or implied by such forward-looking information or statements. Readers are cautioned not to place undue reliance on such forward-looking information or statements. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking information or statements. CannapharmaRx assumes no obligation to update any forward-looking information or statements, even if new information becomes available as a result of future events, new information, or for any other reason except as required by law.

Contact Information:
Brokers and Analysts:
Chesapeake Group
(410) 825-3930

SOURCE: CannaPharmaRx



View source version on accesswire.com:
https://www.accesswire.com/688168/CannaPharmaRx-Acquiring-Oklahoma-Cannabis-Facility

FAQ

What is the acquisition of the Oklahoma cannabis facility by CannaPharmaRx?

CannaPharmaRx is acquiring a cannabis facility in Braman, Oklahoma, with 35,000 square feet of cultivation capacity, expected to generate approximately $21 million in annual revenue.

What is the expected revenue impact of the new facility for CannaPharmaRx?

The Oklahoma facility is expected to contribute to a total projected revenue of $40-$50 million for CannaPharmaRx, combining both the new and existing facilities.

When is the acquisition of the Oklahoma facility expected to close?

The acquisition is expected to close prior to March 31, 2022.

What are the future growth plans of CannaPharmaRx after the acquisition?

CannaPharmaRx plans to achieve significant revenue recognition during early Q2 and is exploring additional expansion opportunities to enhance distribution globally.

CANNAPHARMARX INC

OTC:CPMD

CPMD Rankings

CPMD Latest News

CPMD Stock Data

6.63M
661.88M
0.09%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Calgary